ALX-0171

Phase 2Biologic

AAblynx, a Sanofi company

ALX-0171 is one of 35 biologic programs targeting Respiratory tract infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Respiratory Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Respiratory Tract Infection

#DrugCompanyPhaseTrials

Aquasol E

NNational Eye Institute (NEI)

Approved

1 2

Acetylsalicylic Acid

Bayer

Approved

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 5

Bacille Calmette-Guérin

Roche

Approved

1 6

Veklury

Gilead

Phase 2

1 7

Quietus

Merck & Co.

Phase 2

1 8

Rapivab

BBioCryst Pharmaceuticals

Phase 3

1 9

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 10

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory tract infection3 trials

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

Completed·AAblynx, a Sanofi company·Phase 1/2·NCT02309320·53 enrolled

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Completed·AAblynx, a Sanofi company·Phase 2·NCT02979431·180 enrolled

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Terminated·AAblynx, a Sanofi company·Phase 2·NCT03418571·15 enrolled

Single Ascending Dose1 trial

ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

Completed·AAblynx, a Sanofi company·Phase 1·NCT01483911·60 enrolled

Adult1 trial

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

Completed·AAblynx, a Sanofi company·Phase 1·NCT01909843·24 enrolled

Respiratory Syncytial Virus (RSV) Infection1 trial

Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

Withdrawn·AAblynx, a Sanofi company·Phase 2·NCT03468829

Unspecified1 trial

ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

Completed·AAblynx, a Sanofi company·Phase 1·NCT01875926·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for ALX-0171. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALX-0171 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALX-0171. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ablynx, a Sanofi company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAblynx, a Sanofi company

ALX-0171

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory tract infection3 trials

Single Ascending Dose1 trial

Adult1 trial

Respiratory Syncytial Virus (RSV) Infection1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News